<DOC>
	<DOCNO>NCT00317954</DOCNO>
	<brief_summary>The aim study evaluate renoprotective effect ( i.e . albuminuria- bloodpressure lower effect ) spironolactone 25 mg o.d . type 1 type 2 diabetic patient albuminuria despite recommended antihypertensive treatment .</brief_summary>
	<brief_title>Spironolactone Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Diabetes Mellitus Diabetic Nephropathy Glomerular filtration rate &gt; 30 ml/min/1.73 m2 Blood pressure &gt; 130/80 mm Hg Child bear potential Plasmapotassium &gt; 4.5 mmol/l Breastfeeding Abuse alcohol drug Nondiabetic kidney disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>Spironolactone</keyword>
	<keyword>Aldosterone antagonism</keyword>
	<keyword>Renoprotection</keyword>
</DOC>